Status:
RECRUITING
Duration of Therapeutic Anticoagulation in Patients With Pulmonary Embolism
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Pulmonary Embolism
Eligibility:
All Genders
18+ years
Brief Summary
Current management of intermediate- and high-risk pulmonary embolism is primarily based on curative subcutaneous or intravenous anticoagulation, with or without systemic fibrinolytic therapy or thromb...
Eligibility Criteria
Inclusion
- Adult patient (≥18 years old)
- Hospitalized in the intensive care unit of Hautepierre Hospital (Strasbourg University Hospitals UF 6250) between January 1, 2014, and December 31, 2023
- With a diagnosis of pulmonary embolism confirmed by a thoracic CT angiogram, a thoracoabdominopelvic CT scan, or a lung scan
- Having received anticoagulation with curative-dose unfractionated heparin
Exclusion
- Subjects who have expressed objection to the reuse of their data for scientific research purposes. - Patients diagnosed with pulmonary embolism prior to admission to the intensive care unit and for whom we cannot precisely determine the start date of anticoagulation (precision estimated to the nearest hour).
- Pulmonary embolism not confirmed by contrast imaging (CT angiography)
- Patients who have not received curative anticoagulation (contraindication)
- Patients already receiving curative anticoagulation with UFH at the time of diagnosis
- Patients with low-risk pulmonary embolism defined by an sPESI score of 0
- Subject under court protection, guardianship, or curatorship
Key Trial Info
Start Date :
November 6 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06912009
Start Date
November 6 2024
End Date
December 31 2025
Last Update
December 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Réanimation Médicale - CHU de Strasbourg - France
Strasbourg, France, 67091